227 related articles for article (PubMed ID: 17823882)
21. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
22. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
23. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
24. [Two patients with hypereosinophilic syndrome].
van Ruth S; Lokhorst HM; Bruijnzeel-Koomen CA
Ned Tijdschr Geneeskd; 2006 May; 150(21):1193-7. PubMed ID: 16768285
[TBL] [Abstract][Full Text] [Related]
25. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
26. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
[TBL] [Abstract][Full Text] [Related]
27. The hypereosinophilic syndromes: still more heterogeneity.
Gleich GJ; Leiferman KM
Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
[TBL] [Abstract][Full Text] [Related]
28. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
29. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
[TBL] [Abstract][Full Text] [Related]
30. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
31. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes.
Klion AD
Hematology Am Soc Hematol Educ Program; 2005; ():209-14. PubMed ID: 16304382
[TBL] [Abstract][Full Text] [Related]
33. The hypereosinophilic syndrome: idiopathic or not, that is the question.
Cools J
Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372
[No Abstract] [Full Text] [Related]
34. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
35. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
37. [The Hypereosinophilic Syndromes in Childhood].
Leu T; Simon HU; Hebestreit H; Kunzmann S
Klin Padiatr; 2015 Nov; 227(6-7):308-13. PubMed ID: 26267413
[TBL] [Abstract][Full Text] [Related]
38. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
Wolf D; Gastl G; Rumpold H
Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
[TBL] [Abstract][Full Text] [Related]
39. Treatment of hypereosinophilic syndromes--the first 100 years.
Butterfield JH; Weiler CR
Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
[TBL] [Abstract][Full Text] [Related]
40. Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
Galimberti S; Ciabatti E; Ottimo F; Rossi A; Trombi L; Carulli G; Cervetti G; Matti L; Bianchi G; Petrini M
Clin Exp Rheumatol; 2007; 25(1):17-22. PubMed ID: 17417985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
